BriaCell Therapeutics 3Q FY2026: Net loss $(7.16M), EPS $(0.99) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.BriaCell Therapeutics reported a Q3 FY2026 net loss of $7.16M and EPS of $(0.99), widening from the prior year's $6.13M loss. Year-to-date net loss reached $22.58M. Clinically, the Phase 3 Bria-IMT™ trial for metastatic breast cancer is advancing with over 160–230 patients enrolled and five positive DSMB reviews. The company also secured $2M in NCI SBIR funding, expanded its pipeline with cleared INDs, and increased operational spending to support accelerated clinical enrollment.
BriaCell Therapeutics Corp. reported a net loss of $(7.16M) for the third quarter of fiscal 2026, compared with a net loss of $(6.13M) in the year-ago quarter; diluted loss per share was $(0.99) versus $(16.42) in the prior-year quarter. For the nine months ended April 30, 2026, BriaCell recorded a year-to-date net loss of $(22.58M), up from $(18.22M) a year earlier.
Financial Highlights
- Net loss: $(7.16M) for 3Q FY2026, versus $(6.13M) in the year-ago quarter (wider loss YoY).
- Diluted earnings per share: $(0.99) for 3Q FY2026, versus $(16.42) in the year-ago quarter.
- Net loss (YTD): $(22.58M) for the nine months ended Apr 30, 2026, versus $(18.22M) year-ago (increased loss YoY).
Business Highlights
- Clinical progress: The pivotal Phase 3 Bria-IMT™ trial in metastatic breast cancer is advancing, with more than 160–230+ patients enrolled and five positive Data Safety Monitoring Board (DSMB) reviews reported.
- Efficacy & biomarkers: Phase 2/3 data show benchmark-beating survival outcomes, durable responders, and emerging Th1 biomarker signatures supporting the program.
- Pipeline expansion: Bria-OTS/OTS+ moved to GMP supplies; IND cleared for Bria-BRES+ and manufacturing for Bria-PROS+ completed.
- Collaborations & non-dilutive funding: Participation in the MSK Therapeutics Accelerator cohort, a $2M NCI SBIR award, and collaboration with MSK to support IND and clinical work.
- Operational scale-up: Company increased clinical site additions and CRO, manufacturing and clinical spending to support accelerated enrollment in its trials.
Original SEC Filing: BriaCell Therapeutics Corp. [ BCTX ] - 10-Q - Jun. 09, 2026